about
Nasopharyngeal Bacterial Carriage in the Conjugate Vaccine Era with a Focus on PneumococciDesigning vaccines for the twenty-first century societyMeningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year period.Surveillance for rare infectious diseases: is one passive data source enough for Haemophilus influenzae?Progress in vaccination against Haemophilus influenzae type b in the Americas.Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa.Childhood Hib vaccination and pneumonia and influenza burden in US seniorsProtein carriers of conjugate vaccines: characteristics, development, and clinical trials.Serological protection induced by Haemophilus influenzae Type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed?Haemophilus influenzae type b conjugate vaccines.Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine boosterPotential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in ScotlandHaemophilus influenzae type b carriage and novel bacterial population structure among children in urban Kathmandu, Nepal.Paediatric community-acquired pneumonia: current concept in pharmacological control.Safety and efficacy of meningococcal group C conjugate vaccines.Molecular epidemiology of Haemophilus influenzae type b isolated from children with clinical cases of conjugate vaccine failuresHuman Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccineNaturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in MaliPrevention of Haemophilus influenzae type b disease: past success and future challenges.The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.The effectiveness of conjugate Haemophilus influenzae type B vaccine in The Gambia 14 years after introduction.Hib epiglottitis despite fully vaccinated status.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.The continuing role of Haemophilus influenzae type b carriage surveillance as a mechanism for early detection of invasive disease activity.Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction.Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination?The endgame for serogroup a meningococcal disease in Africa?Conjugate vaccines.Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
P2860
Q26782298-CDC27BBF-E564-4D36-A595-942278D898E8Q27025703-34155ED9-B316-4BF1-A159-274FDAB18B38Q30833747-391425CA-FEDC-4FDE-9DA8-0A3C3EAC7650Q31153135-269920E8-6383-4726-8FC6-E22ACA90F8BCQ33330445-356843F1-696B-4701-97F4-28945C162ADCQ33394304-5D258AF2-4F5A-468D-A674-9E2E371C2BA6Q34044178-BAA1B90E-6F40-44F7-BBA5-B6A70B76EC06Q34170021-7123BC93-9C08-40BF-9735-E95E678353BDQ34190023-BC856A31-AD32-4756-B8F1-82A6318126BAQ34349892-FA14404D-ECEE-43DA-B83A-4FEE64D43AB2Q34431928-25F07E2B-31F9-456F-8815-AF494375999DQ34569142-FAE8C411-7C62-4782-A0E6-4AFE92F5C6A1Q35066923-C8E2CA53-F8A3-4E5F-83F2-F73386DD032EQ35124715-15F7BE94-01A2-491A-99CF-4EE9C5F5F9CEQ35194432-2080ED80-9D8C-4DCF-A933-D5326AEC50B4Q35637844-2A4DC082-414C-49B8-8347-86BE8D7C0017Q35697891-5882AE49-42EF-45FB-AA6C-84F9F9C82C68Q35766567-6C9E0017-B13F-4771-928B-3D9DAEC5819EQ36005810-25D03367-EBDD-432B-AD9B-33750850E49EQ36350560-02AEF85D-CD24-4F94-A96C-9DF2EE3D9198Q37037419-6E5F0EBC-A5BC-47D4-9F37-83A5DFF58DB2Q37077660-7E0E157D-977E-43BF-A304-A75E16EF116FQ37272305-5FF2A038-77E9-4980-95D8-8C267B48F781Q37272533-AA55E5F3-19C2-4DA6-A0CD-CC8CB9ADBE76Q37878485-75461F4B-0DCC-433E-8998-41521C18B50CQ37951530-C3CF636A-0945-40F8-A6B8-9DF40DC8A684Q37959649-55DD24EA-BAA2-469B-99D0-9CF4349FC1A6Q38083114-83018AC6-61B3-4E57-ACE2-67FB5787B342Q38118371-0E6FB604-F3F1-494C-BE92-309AE59B407DQ42265961-68F3DDC2-E8E5-4F33-A98A-399E9CF5B27EQ42577186-C47BACD9-9ABE-4513-8821-7162D938B232Q43098481-560009A1-E5EC-4E1C-B4C9-2DEDC92609B7Q51968253-A889EBD9-B5A3-4935-93B2-58BCDECD7C1AQ57531180-7BF19642-1042-4879-98C8-734A700B02CA
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
The UK Hib vaccine experience
@ast
The UK Hib vaccine experience
@en
The UK Hib vaccine experience
@nl
type
label
The UK Hib vaccine experience
@ast
The UK Hib vaccine experience
@en
The UK Hib vaccine experience
@nl
prefLabel
The UK Hib vaccine experience
@ast
The UK Hib vaccine experience
@en
The UK Hib vaccine experience
@nl
P2860
P356
P1476
The UK Hib vaccine experience
@en
P2093
P2860
P304
P356
10.1136/ADC.86.6.396
P407
P577
2002-06-01T00:00:00Z